
Kartesia in €32m refinancing for Enterprise-backed Nu-Med
Kartesia has provided Enterprise Investors portfolio company Nu-Med with a €32m refinancing package.
The package will go towards refinancing all existing financial debt and supporting Nu-Med in its growth plan.
This is the first deal for Kartesia in Poland. Capital for the deal will be drawn from Kartesia Credit Opportunities (KCO) IV and V funds. The firm's fourth fund closed on €870m in October 2017 and offers debt and equity packages of €10-60m to European small and mid-cap companies. KCO V was registered in March 2019 and, according to Unquote Data, is still fundraising.
Previous funding
Enterprise acquired a minority stake in the company in 2013, drawing equity from its Polish Enterprise Fund VII. The firm had invested €37.4m in the company as of January 2017.
Enterprise put the asset up for sale, with PwC advising, but did not achieve a sale, according to Unquote sister publication Mergermarket.
Company
Headquartered in Elblag, Poland, Nu-Med is a private operator of four oncology centres in Poland and was founded in 2013.
People
Kartesia – Giuseppe Mirante (head of DACH credit opportunities).
Nu-Med Group – Paweł Paczkowski (CEO).
Latest News
Sagard buys Nutrisens from Evolem, Unigrains
Nutrisens management team, led by CEO Georges Devesa, retains a significant stake in the company
Litorina-backed Fractal Gaming Group to list
Intention to list comes four years after the GP acquired the company via its fourth fund
VC-backed Mister Spex buys Tribe
Online optician has previously received VC funding from investors including Grazia Equity and Goldman Sachs
Moonfare, Lexington launch digital secondaries platform
Platform will enable smaller investors to put their secondaries stakes up for sale